RANDOMIZED CONTROL TRIAL: MYCOPHENOLATE MOFETIL IN PATIENTS W/ IGA NEPHROPATHY

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项多中心临床试验测试了霉酚酸酯对维持血管紧张素转换酶抑制剂和鱼油补充剂标准方案的IgA肾病患者减少蛋白尿（通常等同于改善预后）的疗效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This multicenter clinical trial tests the efficacy of Mycophenolate Mofetil in reducing proteinuria, which is usually equated with improvement in prognosis, in patients with IgA Nephropathy who are being maintained on a standard regimen of an angiotensin converting enzyme inhibitor and fish oil supplements.